CN100592373C - 液晶显示面板驱动装置及其驱动方法 - Google Patents

液晶显示面板驱动装置及其驱动方法 Download PDF

Info

Publication number
CN100592373C
CN100592373C CN200710074614A CN200710074614A CN100592373C CN 100592373 C CN100592373 C CN 100592373C CN 200710074614 A CN200710074614 A CN 200710074614A CN 200710074614 A CN200710074614 A CN 200710074614A CN 100592373 C CN100592373 C CN 100592373C
Authority
CN
China
Prior art keywords
pixel
picture
gtg
frame
gray scale
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200710074614A
Other languages
English (en)
Other versions
CN101312015A (zh
Inventor
陈景丰
陈思孝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innolux Shenzhen Co Ltd
Innolux Corp
Original Assignee
Innolux Shenzhen Co Ltd
Innolux Display Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innolux Shenzhen Co Ltd, Innolux Display Corp filed Critical Innolux Shenzhen Co Ltd
Priority to CN200710074614A priority Critical patent/CN100592373C/zh
Priority to US12/154,836 priority patent/US8054268B2/en
Publication of CN101312015A publication Critical patent/CN101312015A/zh
Application granted granted Critical
Publication of CN100592373C publication Critical patent/CN100592373C/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G3/00—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes
    • G09G3/20—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters
    • G09G3/34—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters by control of light from an independent source
    • G09G3/36—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters by control of light from an independent source using liquid crystals
    • G09G3/3611—Control of matrices with row and column drivers
    • G09G3/3648—Control of matrices with row and column drivers using an active matrix
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/02—Improving the quality of display appearance
    • G09G2320/0247—Flicker reduction other than flicker reduction circuits used for single beam cathode-ray tubes
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/02—Improving the quality of display appearance
    • G09G2320/0252—Improving the response speed
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2320/00—Control of display operating conditions
    • G09G2320/02—Improving the quality of display appearance
    • G09G2320/0261—Improving the quality of display appearance in the context of movement of objects on the screen or movement of the observer relative to the screen
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2340/00—Aspects of display data processing
    • G09G2340/16—Determination of a pixel data signal depending on the signal applied in the previous frame
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2360/00—Aspects of the architecture of display systems
    • G09G2360/16—Calculation or use of calculated indices related to luminance levels in display data
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G3/00—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes
    • G09G3/20—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters
    • G09G3/2007—Display of intermediate tones
    • G09G3/2018—Display of intermediate tones by time modulation using two or more time intervals
    • G09G3/2022—Display of intermediate tones by time modulation using two or more time intervals using sub-frames
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G3/00—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes
    • G09G3/20—Control arrangements or circuits, of interest only in connection with visual indicators other than cathode-ray tubes for presentation of an assembly of a number of characters, e.g. a page, by composing the assembly by combination of individual elements arranged in a matrix no fixed position being assigned to or needed to be assigned to the individual characters or partial characters
    • G09G3/2007—Display of intermediate tones
    • G09G3/2077—Display of intermediate tones by a combination of two or more gradation control methods
    • G09G3/2081—Display of intermediate tones by a combination of two or more gradation control methods with combination of amplitude modulation and time modulation

Abstract

一种液晶显示面板驱动装置，其包括一帧存储器、一比较器、一亮度检测器、一画面复杂程度计算器和一灰阶转换器。该比较器用来接收待显示的一帧画面的像素灰阶和该帧存储器输出的上一帧画面的像素灰阶，对应比较该两帧画面各像素灰阶。该亮度检测器用来检测待显示的一帧画面各个像素的亮度值。该画面复杂程度计算器用来计算待显示的一帧画面的画面复杂程度值。该灰阶转换器用来将待显示的一帧画面的像素灰阶转换成多组校正灰阶，该灰阶转换器根据比较器的比较结果、各像素的亮度值和画面复杂程度值，选择输出一组校正灰阶到液晶显示面板。

Description

液晶显示面板驱动装置及其驱动方法
技术领域
本发明是关于一种液晶显示面板驱动装置及其驱动方法。
背景技术
由于液晶显示面板具有轻、薄、耗电小等优点，被广泛应用于电视、笔记本电脑、移动电话等现代化信息设备。目前，液晶显示面板在市场上的应用越来越重要。然而，液晶的反应速度较慢的特性和液晶显示面板的稳态(Hold-Type)发光方式，导致画面存在较严重的拖影现象。
为解决上述拖影现象，业界人士最先提出一种插黑技术，即将画面显示的每一帧分为一第一子时段和一第二子时段，第一子时段显示实际画面，第二子时段显示黑画面。然，由于每两实际画面之间都会***一黑画面，因此人眼会明显感受到画面的闪烁。其次，由于每一帧中都***了黑画面，因此画面整体亮度会将低。
为了改善上述闪烁和亮度降低的现象，业界人士又提出一种插灰技术。请参阅图1，是一种现有技术的液晶显示面板驱动装置的示意图。该液晶显示面板驱动装置10包括一帧存储器11、一比较器12和一灰阶处理器13。该帧存储器11用来接收一待显示的第(m+1)帧画面的像素灰阶V(m+1)，并将其存储的第m帧画面的像素灰阶V(m)输出到该比较器12。其中，m＝0～59。
假设该液晶显示面板14的分辨率为I×J。该比较器12用来接收一整个第m帧画面的像素灰阶V(m)和一待显示的第(m+1)帧画面的像素灰阶V(m+1)，并对应比较第m帧画面各像素的灰阶V(m，i，j)和第(m+1)帧画面各像素的灰阶V(m+1，i，j)，输出对应的比较结果到该灰阶处理器13。其中，V(m，i，j)表示第m帧画面中第(i，j)像素的灰阶，V(m+1，i，j)表示第(m+1)帧画面中第(i，j)像素的灰阶，1≤i≤I，1≤j≤J。
该灰阶处理器13用来接收一待显示的第(m+1)帧画面的像素灰阶V(m+1)，将各个像素的像素灰阶V(m+1，i，j)转换成2组校正灰阶。每一组校正灰阶包括一校正灰阶A和一校正灰阶B。该灰阶处理器13根据该比较器12的比较结果，选择其中一组校正灰阶，并在一帧的连续两个时间段内分别输出校正灰阶A和校正灰阶B到液晶显示面板14。
请参阅图2，是两组校正灰阶对应的亮度值曲线图。其中，校正灰阶1A和校正灰阶1B分别为像素灰阶V(m+1，i，j)第一时间段内对应的灰阶和像素灰阶V(m+1，i，j)第二时间段内对应的灰阶。校正灰阶2A的亮度值大于像素灰阶V(m+1，i，j)的亮度值，校正灰阶2B的亮度值小于像素灰阶V(m+1，i，j)的亮度值，且校正灰阶2A和校正灰阶2B对应的像素的平均亮度值等于像素灰阶V(m+1，i，j)对应的亮度值。
该液晶显示面板驱动装置10的驱动方法包括如下步骤：
a.输出代表一待显示的第(m+1)帧画面的像素灰阶V(m+1)到该帧存储器11和该比较器12，同时该帧存储器11输出一整个第m帧画面的像素灰阶V(m)到该比较器12；
b.该比较器12对应比较第m帧画面各像素的灰阶V(m，i，j)和第(m+1)帧画面各像素的灰阶V(m+1，i，j)，并将各个比较结果输出到该灰阶处理器13；
c.若V(m，i，j)＝V(m+1，i，j)，即第(m+1)帧画面第(i，j)像素是静态显示；则该灰阶处理器13选择校正灰阶1，并在一帧的两个连续时间段内分别输出校正灰阶1A和校正灰阶1B到液晶显示面板14；若V(m，i，j)≠V(m+1，i，j)，即第(m+1)帧第(i，j)像素是动态显示，则该灰阶处理器13选择校正灰阶2，并在一帧中两个连续时间段内分别输出校正灰阶2A和校正灰阶2B到液晶显示面板14。
由于校正灰阶1和校正灰阶2对应的像素的平均亮度值都等于像素灰阶V(m+1，i，j)对应的亮度值，因此该液晶显示面板14的整体画面亮度不变。然而，该液晶显示面板14显示动态画面时，每一帧内都会显示一亮画面和一暗画面，因此该液晶显示面板14仍无法避免闪烁问题，影响画面显示品质。
发明内容
为了解决现有技术液晶显示面板画面显示品质较低的问题，有必要提供一种可提高液晶显示面板画面显示品质的液晶显示面板驱动装置。
为了解决现有技术液晶显示面板画面显示品质较低的问题，还有必要提供一种上述液晶显示面板驱动装置的驱动方法。
一种液晶显示面板驱动装置，其包括一帧存储器、一比较器、一亮度检测器、一画面复杂程度计算器和一灰阶转换器。该帧存储器用来接收待显示的一帧画面的像素灰阶，并输出其存储的上一帧画面的像素灰阶。该比较器用来接收待显示的一帧画面的像素灰阶和该帧存储器输出的上一帧画面的像素灰阶，对应比较该两帧画面各像素的灰阶，并输出对应的比较结果。该亮度检测器用来检测待显示的一帧画面各个像素的亮度值并输出。该画面复杂程度计算器用来计算待显示的一帧画面的画面复杂程度值并输出。该灰阶转换器用来接收待显示的一帧画面的像素灰阶，将各个像素的像素灰阶转换成多组校正灰阶，该灰阶转换器根据该比较器的比较结果、各像素的亮度值和画面复杂程度值，选择输出一组校正灰阶到一液晶显示面板。
上述液晶显示面板驱动装置的驱动方法包括如下步骤：a.代表待显示的一帧画面的像素灰阶输出到该帧存储器、该比较器、该亮度检测器和该画面复杂程度计算器，同时该帧存储器输出上一帧画面的像素灰阶到该比较器；b.该比较器对应比较该两帧画面各像素的灰阶，并将比较结果输出到该灰阶转换器；同时该亮度检测器将各像素的亮度值输出到该灰阶转换器，该画面复杂程度计算器将各阵列的画面复杂程度值输出到该灰阶转换器；c.该灰阶转换器根据该比较器输出的各像素的比较结果、各像素的亮度值和画面复杂程度值选择一组校正灰阶，输出到液晶显示面板。
相较于现有技术，该液晶显示面板驱动装置的灰阶转换器可以将每一帧画面的各像素的像素灰阶转换成多组校正灰阶，且根据各像素的亮度值和像素所在阵列的画面复杂程度值选择一组最合适的校正灰阶，既可有效克服拖影问题、又可有效克服闪烁问题。另，每一组校正灰阶对应的像素的平均显示亮度值可以控制，也可避免画面整体亮度降低的问题。因此，该液晶显示面板驱动装置和驱动方法驱动的液晶显示面板的显示品质较高。
附图说明
图1是一种现有技术的液晶显示面板驱动装置的示意图。
图2是两组校正灰阶对应的亮度值曲线图。
图3是本发明液晶显示面板驱动装置一较佳实施方式的示意图。
图4是比较结果、亮度值、画面复杂程度值与多组校正灰阶的对应关系表。
图5是多组校正灰阶对应的亮度值曲线图。
具体实施方式
请参阅图3，是本发明液晶显示面板驱动装置一较佳实施方式的示意图。该液晶显示面板驱动装置20包括一帧存储器21、一比较器22、一亮度检测器23、一画面复杂程度计算器24和一灰阶转换器25。
该帧存储器21用来接收一待显示的第(m+1)帧画面的像素灰阶V(m+1)，并将其存储的第m帧画面的像素灰阶V(m)输出到该比较器22。其中，m＝0～59。该亮度检测器23用来检测一待显示的第(m+1)帧画面各个像素的亮度值，并将亮度值输出到该灰阶转换器25。
假设该液晶显示面板驱动装置20驱动的液晶显示面板26的分辨率为1024×768。以12列16行为一个阵列，将液晶显示面板26的显示区域分为64个阵列。该画面复杂程度计算器24用来计算第(m+1)帧画面每一个阵列的画面复杂程度值，并将各画面复杂程度值输出到该灰阶转换器25。该画面复杂程度值可通过计算一阵列画面对应的灰阶数量来确定。
该比较器22用来接收一整个第m帧画面的像素灰阶V(m)和一待显示的第(m+1)帧画面的像素灰阶V(m+1)，并对应比较第m帧画面各像素的灰阶V(m，i，j)和第(m+1)帧画面各像素的灰阶V(m+1，i，j)，输出对应的比较结果到该灰阶转换器25。其中，V(m，i，j)表示第m帧画面中第(i，j)像素的灰阶，V(m+1，i，j)表示第(m+1)帧画面中第(i，j)像素的灰阶，1≤i≤I，1≤j≤J。
该灰阶转换器25用来接收一整个第(m+1)帧画面的像素灰阶V(m+1)，将各个像素的像素灰阶V(m+1，i，j)转换成多组校正灰阶。每一组校正灰阶包括一校正灰阶A和一校正灰阶B。该灰阶转换器25根据该比较器22输出的比较结果、第(m+1)帧画面该像素的亮度值和该像素所在阵列的画面复杂程度值，选择一组校正灰阶，并在一帧的连续两个时间段内分别输出校正灰阶A和校正灰阶B到液晶显示面板26。每一组校正灰阶对应的平均亮度值等于像素灰阶V(m+1，i，j)对应的亮度值。
请参阅图4，是该比较器22输出的第m帧画面第(i，j)像素的比较结果、第m帧画面第(i，j)像素的亮度值、第m帧画面第(i，j)像素所在阵列的画面复杂程度值与多组校正灰阶的对应关系表。由图4可以看出，第(i，j)像素的亮度值分为X个等级(X≥2)，第(i，j)像素所在阵列的画面复杂程度值分为Y个等级(Y≥2)，校正灰阶为(X+Y)组。其中，亮度值等级越高，则表明亮度值越大；画面复杂程度值等级越高，则表明画面复杂程度值越大。
请参阅图5，是多组校正灰阶对应的亮度值曲线图。其中，校正灰阶1A和校正灰阶1B分别为像素灰阶V(m+1，i，j)第一时间段内对应的灰阶和像素灰阶V(m+1，i，j)第二时间段内对应的灰阶。该液晶显示面板驱动装置20的驱动方法包括如下步骤：
a.输出代表一整个第(m+1)帧画面的像素灰阶V(m+1)到该帧存储器21、该比较器22、该亮度检测器23和该画面复杂程度计算器24，同时该帧存储器21输出一整个第m帧画面的像素灰阶V(m)到该比较器22；
b.该比较器22对应比较第m帧画面各像素的灰阶V(m，i，j)和第(m+1)帧画面各像素的灰阶V(m+1，i，j)，并将比较结果输出到该灰阶转换器25；同时该亮度检测器23将各像素的亮度值输出到该灰阶转换器25，该画面复杂程度计算器24将各阵列的画面复杂程度值输出到该灰阶转换器25；
c.该灰阶转换器25会根据该比较器22输出的第(i，j)像素的比较结果、该第(i，j)像素的亮度值和第(i，j)像素所在阵列的画面复杂程度值选择一组校正灰阶，并在一帧的两个连续时间段内分别输出校正灰阶A和校正灰阶B到液晶显示面板26；
该灰阶转换器25选择校正灰阶的方法如下：
若V(m，i，j)＝V(m+1，i，j)，即第(m+1)帧第(i，j)像素是静态显示；则该灰阶转换器25选择校正灰阶1，并在一帧的两个连续时间段内分别输出校正灰阶1A和校正灰阶1B到液晶显示面板26；
若V(m，i，j)≠V(m+1，i，j)，即第(m+1)帧第(i，j)像素是动态显示，则分为以下几种选择方法：
若第(i，j)像素的亮度值处于第1等级(即最暗)，且第(i，j)像素所在阵列的画面复杂程度值处于第Y等级(即最复杂)，则画面最难分辨，选择校正灰阶(X+Y-1)。如图5所示，校正灰阶(X+Y-1)的振幅最大，使画面容易分辨。
若第(i，j)像素的亮度值处于第1等级，且第(i，j)像素所在阵列的画面复杂程度值处于第(Y-1)等级，则选择校正灰阶(X+Y-2)。如图5所示，校正灰阶(X+Y-2)的振幅仅小于校正灰阶(X+Y-1)的振幅。
若第(i，j)像素的亮度值处于第1等级，且第(i，j)像素所在阵列的画面复杂程度值处于第1等级，则选择校正灰阶X。
若第(i，j)像素的亮度值处于第2等级，且第(i，j)像素所在阵列的画面复杂程度值处于第Y等级，则选择校正灰阶(X+Y-2)。
若第(i，j)像素的亮度值处于第2等级，且第(i，j)像素所在阵列的画面复杂程度值处于第(Y-1)等级，则选择校正灰阶(X+Y-3)。
若第(i，j)像素的亮度值处于第2等级，且第(i，j)像素所在阵列的画面复杂程度值处于第1等级，则选择校正灰阶(X-1)。
依次类推，若第(i，j)像素的亮度值处于第X等级(即最亮)，且第(i，j)像素所在阵列的画面复杂程度值处于第1等级(即最简单)，则选择校正灰阶2。如图5所示，校正灰阶2的振幅仅大于校正灰阶1的振幅。
相较于现有技术，该液晶显示面板驱动装置20的灰阶转换器25可以将每一帧画面的各像素的像素灰阶V(m+1，i，j)转换成多组校正灰阶，且根据各像素的亮度值和像素所在阵列的画面复杂程度值选择一组最合适的校正灰阶，既可有效克服拖影问题、又可有效克服闪烁问题。另，每一组校正灰阶对应的像素显示亮度值可以控制为等于像素灰阶V(m+1，i，j)对应的亮度值，也可避免画面整体亮度降低的问题。因此，利用该液晶显示面板驱动装置20和驱动方法驱动的液晶显示面板26的显示品质较高。
该液晶显示面板驱动装置20也可具其它多种变更设计，如：根据需要，也可以3列4行或24列32行等为一个阵列，将一帧画面分为多个阵列，以便该画面复杂程度计算器24计算每一阵列的画面复杂程度值；当液晶显示面板26较小时，也可以一整个帧画面作为一个阵列，该画面复杂程度计算器24用来计算一帧画面的画面复杂程度值。

Claims (10)

1.一种液晶显示面板驱动装置，其包括一帧存储器和一比较器，该帧存储器用来接收待显示的一帧画面的像素灰阶，并输出其存储的上一帧画面的像素灰阶，该比较器用来接收待显示的一帧画面的像素灰阶和该帧存储器输出的上一帧画面的像素灰阶，对应比较该两帧画面各像素的灰阶，并输出对应的比较结果，其特征在于：该液晶显示面板驱动装置进一步包括一亮度检测器、一画面复杂程度计算器和一灰阶转换器，该亮度检测器用来检测待显示的一帧画面各个像素的亮度值并输出，该画面复杂程度计算器，用来计算待显示的一帧画面的画面复杂程度值并输出，该灰阶转换器用来接收待显示的一帧画面的像素灰阶，将各个像素的像素灰阶转换成多组校正灰阶，该灰阶转换器根据该比较器的比较结果、各像素的亮度值和画面复杂程度值，选择输出一组校正灰阶到一液晶显示面板。
2.如权利要求1所述的液晶显示面板驱动装置，其特征在于：以一帧画面中12列16行像素为一个阵列，将一帧画面分为多个阵列，该画面复杂程度计算器用来计算待显示的每一个阵列的画面复杂程度值，并将各画面复杂程度值输出到该灰阶转换器。
3.如权利要求2所述的液晶显示面板驱动装置，其特征在于：该画面复杂程度值通过计算一阵列画面对应的灰阶数量来确定。
4.如权利要求1所述的液晶显示面板驱动装置，其特征在于：每一组校正灰阶对应的像素的平均亮度值等于像素灰阶使该像素达到的亮度值。
5.如权利要求1所述的液晶显示面板驱动装置，其特征在于：每一组校正灰阶包括一校正灰阶A和一校正灰阶B，校正灰阶A对应的像素的亮度值大于像素灰阶使该像素达到的亮度值，校正灰阶B对应的像素的亮度值小于像素灰阶使该像素达到的亮度值，该灰阶转换器在一帧的连续两个时间段内分别输出校正灰阶A和校正灰阶B到液晶显示面板。
6.如权利要求1所述的液晶显示面板驱动装置的驱动方法，其包括如下步骤：
a.代表待显示的一帧画面的像素灰阶输出到该帧存储器、该比较器、该亮度检测器和该画面复杂程度计算器，同时该帧存储器输出上一帧画面的像素灰阶到该比较器；
b.该比较器对应比较该两帧画面各像素的灰阶，并将比较结果输出到该灰阶转换器；同时该亮度检测器将各像素的亮度值输出到该灰阶转换器，该画面复杂程度计算器将各阵列的画面复杂程度值输出到该灰阶转换器；和
c.该灰阶转换器根据该比较器输出的各像素的比较结果、各像素的亮度值和画面复杂程度值选择一组校正灰阶，输出到液晶显示面板。
7.如权利要求6所述的液晶显示面板驱动装置的驱动方法，其特征在于：步骤b中，将一帧画面分为多个阵列，该画面复杂程度计算器用来计算各阵列的画面复杂程度值。
8.如权利要求7所述的液晶显示面板驱动装置的驱动方法，其特征在于：步骤c中，若该比较器输出的像素的比较结果为相等，则该灰阶转换器选择校正灰阶1，并在一帧的两个连续时间段内分别输出校正灰阶1A和校正灰阶1B到液晶显示面板，且校正灰阶1A等于校正灰阶1B也等于该像素的像素灰阶。
9.如权利要求7所述的液晶显示面板驱动装置的驱动方法，其特征在于：步骤c中，若该比较器输出的像素的比较结果为不等，则该灰阶转换器根据该像素的亮度值和该像素所在阵列的画面复杂程度值选择一组校正灰阶，并在一帧的两个连续时间段内分别输出到液晶显示面板。
10.如权利要求9所述的液晶显示面板驱动装置的驱动方法，其特征在于：步骤c中，将各像素的亮度值分为X个等级，X≥2，将各像素所在阵列的画面复杂程度值分为Y个等级，Y≥2，若该比较器输出的像素的比较结果为不等，且该像素的亮度值最小和该像素所在阵列的画面复杂程度值最大，则选择一组振幅最大的校正灰阶；若该比较器输出的比较结果为不等，且该像素的亮度值最大和该像素所在阵列的画面复杂程度值最小，则选择一组振幅最小的校正灰阶。
CN200710074614A 2007-05-25 2007-05-25 液晶显示面板驱动装置及其驱动方法 Expired - Fee Related CN100592373C (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200710074614A CN100592373C (zh) 2007-05-25 2007-05-25 液晶显示面板驱动装置及其驱动方法
US12/154,836 US8054268B2 (en) 2007-05-25 2008-05-27 Liquid crystal display device having pairs of compensating gradations and method for driving same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200710074614A CN100592373C (zh) 2007-05-25 2007-05-25 液晶显示面板驱动装置及其驱动方法

Publications (2)

Publication Number Publication Date
CN101312015A CN101312015A (zh) 2008-11-26
CN100592373C true CN100592373C (zh) 2010-02-24

Family

ID=40100631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200710074614A Expired - Fee Related CN100592373C (zh) 2007-05-25 2007-05-25 液晶显示面板驱动装置及其驱动方法

Country Status (2)

Country Link
US (1) US8054268B2 (zh)
CN (1) CN100592373C (zh)

Families Citing this family (433)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101922788B1 (ko) 2007-09-26 2018-11-27 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
BRPI1006270B1 (pt) 2009-03-25 2022-08-16 Genentech, Inc Anticorpo anti-a5ss1, imunoconjugado, composição farmacêutica, método in vitro ou ex vivo para detectar a proteína a5ss1, uso de um anticorpo e kit para detectar a proteína a5ss1
CN102024403B (zh) * 2009-09-16 2013-01-16 群康科技(深圳)有限公司 改善显示器拖影现象和轨影现象的方法与相关的显示器
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
SG183333A1 (en) 2010-02-18 2012-09-27 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
EP2550295A1 (en) 2010-03-24 2013-01-30 F. Hoffmann-La Roche AG Anti-lrp6 antibodies
MX336001B (es) 2010-06-18 2016-01-07 Genentech Inc Anticuerpos anti-axl y metodos de uso.
AU2011274528B2 (en) 2010-07-09 2015-04-23 Genentech, Inc. Anti-neuropilin antibodies and methods of use
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
JP2013541501A (ja) 2010-08-03 2013-11-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 慢性リンパ性白血病（ｃｌｌ）のバイオマーカー
CA2805564A1 (en) 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
KR101653030B1 (ko) 2010-08-13 2016-08-31 로슈 글리카트 아게 항-테나신-c a２ 항체 및 이의 사용 방법
NZ703653A (en) 2010-08-13 2016-09-30 Roche Glycart Ag Anti-fap antibodies and methods of use
CA2808236A1 (en) 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
PE20140238A1 (es) 2010-11-10 2014-03-07 Genentech Inc Metodos y composiciones para inmunoterapia para enfermedad neural
MY188365A (en) 2010-12-16 2021-12-06 Genentech Inc Diagnosis and treatments relating to th2 inhibition
UA115641C2 (uk) 2010-12-20 2017-11-27 Дженентек, Інк. Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить
KR20130118925A (ko) 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
JP2014502607A (ja) 2011-01-03 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｄｉｇ抗体およびペプチドと結合体化しているジゴキシゲニンの複合体の薬学的組成物
EP2691417B1 (en) 2011-03-29 2018-08-01 Roche Glycart AG Antibody fc variants
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
LT2710035T (lt) 2011-05-16 2017-06-26 F. Hoffmann-La Roche Ag Fgfr1 agonistai ir jų naudojimo būdai
EP2721067B1 (en) 2011-06-15 2019-07-31 F.Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
CN107090038A (zh) 2011-06-30 2017-08-25 霍夫曼-拉罗奇有限公司 抗c‑met抗体配制剂
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
CA2844141A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Anti-mcsp antibodies
RU2605390C2 (ru) 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
EP2748200B1 (en) 2011-08-23 2018-04-11 Roche Glycart AG Fc-free antibodies comprising two fab fragments and methods of use
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
AR087918A1 (es) 2011-09-19 2014-04-23 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
AU2012319150B2 (en) 2011-10-05 2017-08-17 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
ES2687951T3 (es) 2011-10-14 2018-10-30 F. Hoffmann-La Roche Ag Anticuerpos anti-HtrA1 y procedimientos de uso
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
IN2014CN03062A (zh) 2011-10-28 2015-07-31 Hoffmann La Roche
RU2014124842A (ru) 2011-11-21 2015-12-27 Дженентек, Инк. Очистка анти-с-мет антител
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
CN113896787A (zh) 2011-12-22 2022-01-07 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
MX2014007262A (es) 2011-12-22 2014-08-01 Hoffmann La Roche Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.
SG11201403223PA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
EP2804630B1 (en) 2012-01-18 2017-10-18 F. Hoffmann-La Roche AG Methods of using fgf19 modulators
PE20141561A1 (es) 2012-01-18 2014-11-12 Genentech Inc Anticuerpos anti-lrp5 y metodos de uso
TWI464720B (zh) * 2012-02-02 2014-12-11 Novatek Microelectronics Corp 液晶顯示驅動方法及顯示裝置
EP2812350B1 (en) 2012-02-11 2019-04-03 F.Hoffmann-La Roche Ag R-spondin translocations and methods using the same
TR201808458T4 (tr) 2012-02-15 2018-07-23 Hoffmann La Roche FC-reseptör bazlı afinite kromatografisi.
PT2825558T (pt) 2012-03-13 2019-07-11 Hoffmann La Roche Terapêutica combinada para o tratamento do cancro do ovário
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
WO2013177470A1 (en) 2012-05-23 2013-11-28 Genentech, Inc. Selection method for therapeutic agents
EP2861624A1 (en) 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anti-pcsk9 antibodies, formulations, dosing, and methods of use
KR20150030755A (ko) 2012-07-04 2015-03-20 에프. 호프만-라 로슈 아게 항-바이오틴 항체 및 사용 방법
PL2869837T3 (pl) 2012-07-04 2017-03-31 F.Hoffmann-La Roche Ag Przeciwciała przeciw teofilinie i sposoby ich stosowania
EP3138580B1 (en) 2012-07-04 2021-03-03 F. Hoffmann-La Roche AG Covalently linked antigen-antibody conjugates
JP6309518B2 (ja) 2012-07-05 2018-04-11 ジェネンテック， インコーポレイテッド 発現及び分泌システム
EA201590173A1 (ru) 2012-07-09 2015-09-30 Дженентек, Инк. Иммуноконъюгаты, содержащие антитела к cd22
KR20150030753A (ko) 2012-07-09 2015-03-20 제넨테크, 인크. 항-cd79b 항체를 포함하는 면역접합체
EP2869849A1 (en) 2012-07-09 2015-05-13 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
MX2015000314A (es) 2012-07-09 2015-04-10 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados.
BR112015002681A2 (pt) 2012-08-07 2018-08-28 Genentech Inc método para tratar um paciente e kit
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
PE20150956A1 (es) 2012-11-08 2015-06-20 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3
EA201590731A1 (ru) 2012-11-13 2015-11-30 Дженентек, Инк. Антитела к гемагглютинину и способы применения
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
CA2896259A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Anti-mcsp antibodies
CA2902263A1 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
AU2014239903A1 (en) 2013-03-14 2015-09-17 Genentech, Inc. Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
KR20150127199A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 항-b7-h4 항체 및 면역접합체
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
SG11201507333XA (en) 2013-03-15 2015-10-29 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
KR20150128707A (ko) 2013-03-15 2015-11-18 제넨테크, 인크. 간암의 진단 및 치료를 위한 조성물 및 방법
MX2015012326A (es) 2013-03-15 2016-03-08 Genentech Inc Anticuerpos anti-crth2 y su uso.
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
MX2015015060A (es) 2013-04-29 2016-02-25 Hoffmann La Roche Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
TWI747803B (zh) 2013-04-29 2021-12-01 瑞士商赫孚孟拉羅股份公司 人類結合ｆｃｒｎ之經修飾抗體及使用方法
EP3327034A1 (en) 2013-04-29 2018-05-30 F. Hoffmann-La Roche AG Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
PL3594240T3 (pl) 2013-05-20 2024-04-02 F. Hoffmann-La Roche Ag Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CA2922889A1 (en) 2013-09-17 2015-03-26 Genentech, Inc. Methods of using anti-lgr5 antibodies
EP3049437A1 (en) 2013-09-27 2016-08-03 F. Hoffmann-La Roche AG Thermus thermophilus slyd fkbp domain specific antibodies
KR102105102B1 (ko) * 2013-10-10 2020-04-27 삼성전자주식회사 디스플레이 장치 및 그 디스플레이 방법
JP2016537965A (ja) 2013-10-11 2016-12-08 ジェネンテック， インコーポレイテッド Ｎｓｐ４阻害剤及び使用方法
CA2925598A1 (en) 2013-10-18 2015-04-23 Genentech, Inc. Anti-rspo antibodies and methods of use
MX2016005159A (es) 2013-10-23 2016-07-05 Genentech Inc Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
RU2697098C1 (ru) 2013-11-21 2019-08-12 Ф.Хоффманн-Ля Рош Аг Антитела к альфа-синуклеину и способы применения
MX2016007576A (es) 2013-12-13 2016-10-03 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33.
CN105899535A (zh) 2013-12-17 2016-08-24 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
EP3527587A1 (en) 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
RU2719487C2 (ru) 2013-12-17 2020-04-17 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с компонентами сигнального пути pd-1, и таксанов
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
CN103714751B (zh) 2013-12-30 2016-06-22 北京京东方光电科技有限公司 像素阵列及其驱动方法、显示面板和显示装置
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
CN105873616B (zh) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 共价连接的多肽毒素-抗体缀合物
JP6476194B2 (ja) 2014-01-03 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗ハプテン／抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
CN105873615B (zh) 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 共价连接的helicar-抗helicar抗体缀合物及其用途
MX2016008190A (es) 2014-01-06 2016-10-21 Hoffmann La Roche Modulos de lanzadera de barrera cerebral sanguinea monovalente.
KR20160107190A (ko) 2014-01-15 2016-09-13 에프. 호프만-라 로슈 아게 변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
US20170043034A1 (en) 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
AU2015214058B2 (en) 2014-02-08 2020-07-09 Genentech, Inc. Methods of treating Alzheimer's Disease
EP3102230B1 (en) 2014-02-08 2021-04-28 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
ES2685424T3 (es) 2014-02-12 2018-10-09 F. Hoffmann-La Roche Ag Anticuerpos anti-Jagged1 y procedimientos de uso
WO2015127405A2 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
CN106103730B (zh) 2014-03-14 2021-06-08 豪夫迈·罗氏有限公司 用于分泌异源多肽的方法和组合物
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
JP6588461B2 (ja) 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
UA121112C2 (uk) 2014-03-31 2020-04-10 Дженентек, Інк. Антитіло до ox40 та його застосування
CN113092788A (zh) 2014-04-02 2021-07-09 豪夫迈·罗氏有限公司 检测多特异性抗体轻链错配的方法
BR112016024319B1 (pt) 2014-04-18 2024-01-23 Acceleron Pharma Inc USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
KR20170003582A (ko) 2014-05-22 2017-01-09 제넨테크, 인크. 항-gpc3 항체 및 면역접합체
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
WO2015191715A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
WO2016005545A1 (en) 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
WO2016007775A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
EP3169801A1 (en) 2014-07-14 2017-05-24 F. Hoffmann-La Roche AG Diagnostic methods and compositions for treatment of glioblastoma
AR101848A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos de anti-b7-h4 e inmunoconjugados
SG10201804931QA (en) 2014-09-12 2018-07-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
PE20170935A1 (es) 2014-09-12 2017-07-13 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
CA2957148A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
EP3223865A4 (en) 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
BR112017009159A2 (pt) 2014-11-03 2018-03-06 Genentech, Inc. métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
CA2966523A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
MX2017005930A (es) 2014-11-05 2017-06-30 Genentech Inc Metodo de produccion de proteinas de cadena doble en bacterias.
WO2016073794A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
US20160152720A1 (en) 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
RS59340B1 (sr) 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
MX2017005150A (es) 2014-11-06 2017-08-08 Hoffmann La Roche Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド 抗インターロイキン−３３抗体及びその使用
WO2016077369A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Animal model for nephropathy and agents for treating the same
US10160795B2 (en) 2014-11-14 2018-12-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to Ebola virus glycoprotein and their use
EP3221360A1 (en) 2014-11-17 2017-09-27 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
RU2753902C2 (ru) 2014-11-20 2021-08-24 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CN107108739B (zh) 2014-12-05 2022-01-04 豪夫迈·罗氏有限公司 抗CD79b抗体和使用方法
CN107207591A (zh) 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 血脑屏障受体抗体及使用方法
SI3233921T1 (sl) 2014-12-19 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Protitelesa proti C5 in postopki za uporabo
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CN113956354A (zh) 2015-01-22 2022-01-21 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2016149276A1 (en) 2015-03-16 2016-09-22 Genentech, Inc. Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US10562960B2 (en) 2015-03-20 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use
JP6944924B2 (ja) 2015-03-23 2021-10-06 ジョンス セラピューティクス， インコーポレイテッド Ｉｃｏｓに対する抗体
MY186708A (en) 2015-04-03 2021-08-11 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
KR20180002659A (ko) 2015-04-06 2018-01-08 악셀레론 파마 인코포레이티드 Tgf-베타 슈퍼패밀리 유형 i 및 유형 ii 수용체 이형다합체들과 이의 용도
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
AU2016246695A1 (en) 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
EP3286315B1 (en) 2015-04-24 2021-05-26 F. Hoffmann-La Roche AG Methods of identifying bacteria comprising binding polypeptides
EP3288981A1 (en) 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
EP3936524A3 (en) 2015-05-11 2022-06-15 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
SI3294770T1 (sl) 2015-05-12 2021-01-29 F. Hoffmann-La Roche Ag Terapevtski in diagnostični postopki za raka
JP2018520658A (ja) 2015-05-29 2018-08-02 ジェネンテック， インコーポレイテッド ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
AU2016270625B2 (en) 2015-05-29 2022-10-06 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2016196679A1 (en) 2015-06-02 2016-12-08 Genentech, Inc. Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
SG10201911349YA (en) 2015-06-05 2020-01-30 Genentech Inc Anti-tau antibodies and methods of use
AU2016274584A1 (en) 2015-06-08 2018-01-04 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
CN107810011A (zh) 2015-06-08 2018-03-16 豪夫迈·罗氏有限公司 使用抗ox40抗体治疗癌症的方法
CA2988982A1 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
AR104987A1 (es) 2015-06-15 2017-08-30 Genentech Inc Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
LT3310814T (lt) 2015-06-16 2023-10-10 F. Hoffmann-La Roche Ag Humanizuoti ir subrendusio giminingumo antikūnai prieš fcrh5 ir jų naudojimo būdai
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2016205200A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
MX2017016169A (es) 2015-06-17 2018-08-15 Genentech Inc Anticuerpos anti-her2 y metodos de uso.
CN107771076A (zh) 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
MX2017016645A (es) 2015-06-29 2018-11-09 Genentech Inc Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
KR20180035884A (ko) 2015-08-04 2018-04-06 악셀레론 파마 인코포레이티드 골수증식성 장애를 치료하기 위한 방법
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP6914919B2 (ja) 2015-08-28 2021-08-04 ジェネンテック， インコーポレイテッド 抗ヒプシン抗体及びその使用
CN108271372B (zh) 2015-09-18 2021-07-09 中外制药株式会社 Il-8-结合抗体及其应用
IL257565B1 (en) 2015-09-23 2024-04-01 Genentech Inc Improved variants of anti-VEGF antibodies
EP3662930A1 (en) 2015-09-24 2020-06-10 AbVitro LLC Hiv antibody compositions and methods of use
CA2997799A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-pd1 antibodies and methods of use
AU2016329120B2 (en) 2015-10-02 2023-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory TNF receptor
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
EP3365372A1 (en) 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
RU2022103665A (ru) 2015-10-23 2022-03-05 Еурека Терапьютикс, Инк. Химерные конструкции антитело/t-клеточный рецептор и их применения
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
CN115160439A (zh) 2015-10-30 2022-10-11 豪夫迈·罗氏有限公司 抗-HtrA1抗体及其使用方法
EP3371217A1 (en) 2015-11-08 2018-09-12 H. Hoffnabb-La Roche Ag Methods of screening for multispecific antibodies
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
BR112018003984A2 (pt) 2015-12-09 2018-09-25 Hoffmann La Roche anticorpos
AU2016372930B2 (en) 2015-12-18 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
US20200270365A1 (en) 2016-01-05 2020-08-27 Jiangsu Hengrui Medicine Co., Ltd. Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
WO2017118675A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
BR112018014762A2 (pt) 2016-01-20 2018-12-26 Genentech Inc método de tratamento da doença de alzheimer (da) precoce
CN109196121B (zh) 2016-02-29 2022-01-04 基因泰克公司 用于癌症的治疗和诊断方法
CA3016552A1 (en) 2016-03-15 2017-09-21 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3443004A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3 antibodies and methods of use
EP3443120A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
KR20190003958A (ko) 2016-04-15 2019-01-10 제넨테크, 인크. 암의 치료 및 모니터링 방법
MA56474A (fr) 2016-05-02 2022-05-11 Hoffmann La Roche Contorsbody - liant de cible à chaîne unique
JP7089483B2 (ja) 2016-05-11 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 修飾された抗テネイシン抗体及び使用方法
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN110603266A (zh) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
WO2017211731A1 (en) 2016-06-06 2017-12-14 F. Hoffmann-La Roche Ag Fusion proteins for ophthalmology with increased eye retention
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN116143918A (zh) 2016-06-24 2023-05-23 豪夫迈·罗氏有限公司 抗聚泛素多特异性抗体
JP6983824B2 (ja) 2016-07-04 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規抗体フォーマット
CN116531490A (zh) 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
KR20190040972A (ko) 2016-07-27 2019-04-19 악셀레론 파마 인코포레이티드 골섬유증 치료 방법 및 조성물
MX2018015721A (es) 2016-07-29 2019-05-27 Chugai Pharmaceutical Co Ltd Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3515932B1 (en) 2016-09-19 2023-11-22 F. Hoffmann-La Roche AG Complement factor based affinity chromatography
SI3528838T1 (sl) 2016-09-23 2023-10-30 F. Hoffmann-La Roche Ag Uporabe IL-13 antagonistov za zdravljenje atopijskega dermatitisa
WO2018067740A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
TWI775781B (zh) 2016-10-06 2022-09-01 美商建南德克公司 癌症之治療性及診斷性方法
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
US11555076B2 (en) 2016-10-29 2023-01-17 Genentech, Inc. Anti-MIC antibodies and methods of use
HUE057559T2 (hu) 2016-11-02 2022-06-28 Jounce Therapeutics Inc PD-1 elleni antitestek és alkalmazásaik
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AU2017373884A1 (en) 2016-12-07 2019-05-30 Ac Immune Sa Anti-tau antibodies and methods of their use
AU2017373889A1 (en) 2016-12-07 2019-06-06 Ac Immune Sa Anti-Tau antibodies and methods of use
WO2018114877A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies
BR112019010294A2 (pt) 2016-12-21 2019-09-03 Hoffmann La Roche método para a produção enzimática de um anticorpo, anticorpo e formulação farmacêutica
EP3559250A1 (en) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
EP3568468A4 (en) 2017-01-12 2020-12-30 Eureka Therapeutics, Inc. RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
CA3051700A1 (en) 2017-02-10 2018-08-16 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
US11021535B2 (en) 2017-02-10 2021-06-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CN110546277A (zh) 2017-03-01 2019-12-06 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
EP3600442A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
TW201842936A (zh) 2017-03-22 2018-12-16 美商建南德克公司 水凝膠交聯化的玻尿酸前藥組合物及方法
SG11201908784TA (en) 2017-03-27 2019-10-30 Hoffmann La Roche Improved antigen binding receptor formats
CA3056837A1 (en) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptors
CA3059615A1 (en) 2017-04-21 2018-10-25 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
IL310182A (en) 2017-04-26 2024-03-01 Eureka Therapeutics Inc ׂ A Delaware Corp Structures of chimeric antibody/T-cell receptor and uses thereof
KR20200012860A (ko) 2017-04-26 2020-02-05 유레카 쎄라퓨틱스, 인코포레이티드 글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
US20220135670A1 (en) 2017-04-27 2022-05-05 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
US11168129B2 (en) 2017-05-15 2021-11-09 University Of Rochester Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
JP2020527351A (ja) 2017-07-21 2020-09-10 ジェネンテック， インコーポレイテッド がんの治療法及び診断法
KR20200033798A (ko) 2017-08-03 2020-03-30 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
EP3704150A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG The compbody - a multivalent target binder
BR112020008031A2 (pt) 2017-11-01 2020-10-27 F. Hoffmann-La Roche Ag anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica
TW201923089A (zh) 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法
CN111492243A (zh) 2017-12-21 2020-08-04 豪夫迈·罗氏有限公司 用于新颖抗原结合模块的特异性测试的car-t细胞测定法
EP3729080B1 (en) 2017-12-21 2023-04-19 F. Hoffmann-La Roche AG Universal reporter cell assay for specificity test of novel antigen binding moieties
TW201929907A (zh) 2017-12-22 2019-08-01 美商建南德克公司 Pilra結合劑用於治療疾病之用途
EP4219559A3 (en) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
EP3732202A4 (en) 2017-12-28 2022-06-15 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
US20220135687A1 (en) 2017-12-28 2022-05-05 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1
CN111886246A (zh) 2017-12-29 2020-11-03 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
CA3088649A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
JP7268038B2 (ja) 2018-01-31 2023-05-02 アレクトル エルエルシー 抗ｍｓ４ａ４ａ抗体及びその使用方法
SG11202007390YA (en) 2018-02-08 2020-08-28 Genentech Inc Bispecific antigen-binding molecules and methods of use
KR102417088B1 (ko) 2018-02-09 2022-07-07 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
TW202000702A (zh) 2018-02-26 2020-01-01 美商建南德克公司 用於抗ｔｉｇｉｔ拮抗劑抗體及抗ｐｄ－ｌ１拮抗劑抗體治療之投藥
CN111742219A (zh) 2018-03-01 2020-10-02 豪夫迈·罗氏有限公司 用于新颖靶抗原结合模块的特异性测定法
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US11840568B2 (en) 2018-04-02 2023-12-12 Mab-Venture Biopharm Co., Ltd. Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof
JP2021520209A (ja) 2018-04-04 2021-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌患者における腫瘍抗原を検出するための診断アッセイ
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
WO2019192973A1 (en) 2018-04-04 2019-10-10 F. Hoffmann-La Roche Ag Diagnostic assays to detect tumor antigens in cancer patients
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
EP3787678A1 (en) 2018-05-03 2021-03-10 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
US11319373B2 (en) 2018-05-25 2022-05-03 Alector Llc Anti-SIRPA antibodies and methods of use thereof
WO2019246557A1 (en) 2018-06-23 2019-12-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
KR20210025614A (ko) 2018-06-29 2021-03-09 알렉터 엘엘씨 항-sirp-베타1 항체 및 그의 사용 방법
FI3618928T3 (fi) 2018-07-13 2023-04-21 Alector Llc Anti-sortiliini-vasta-aineita ja menetelmiä niiden käyttämiseksi
KR20210034622A (ko) 2018-07-18 2021-03-30 제넨테크, 인크. Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
SG11202003531WA (en) 2018-08-10 2020-05-28 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
AR119259A1 (es) 2018-08-31 2021-12-09 Alector Llc Anticuerpos anti-cd33 y métodos de uso de los mismos
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019342099A1 (en) 2018-09-19 2021-04-08 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
EP4249917A3 (en) 2018-09-21 2023-11-08 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
CN113196061A (zh) 2018-10-18 2021-07-30 豪夫迈·罗氏有限公司 肉瘤样肾癌的诊断和治疗方法
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3877407A1 (en) 2018-11-05 2021-09-15 F. Hoffmann-La Roche AG Methods of producing two chain proteins in prokaryotic host cells
SG11202105010UA (en) 2018-11-16 2021-06-29 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
BR112021010908A2 (pt) 2018-12-06 2021-08-31 Genentech, Inc. Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
US20220089694A1 (en) 2018-12-20 2022-03-24 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
EP3898667A2 (en) 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Modified antibody fcs and methods of use
KR20210107025A (ko) 2018-12-21 2021-08-31 제넨테크, 인크. 세포사멸에 내성인 세포주를 사용한 폴리펩티드 생산 방법
AU2020211976A1 (en) 2019-01-23 2021-07-15 Genentech, Inc. Methods of producing multimeric proteins in eukaryotic host cells
CN113329770A (zh) 2019-01-24 2021-08-31 中外制药株式会社 新型癌抗原及所述抗原的抗体
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CA3130695A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
MX2021010565A (es) 2019-03-08 2021-10-13 Genentech Inc Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
CN113631910A (zh) 2019-03-29 2021-11-09 豪夫迈·罗氏有限公司 细胞表面蛋白质相互作用的调节剂及其相关方法和组合物
AU2020258480A1 (en) 2019-04-19 2021-10-21 Genentech, Inc. Anti-mertk antibodies and their methods of use
WO2020227228A2 (en) 2019-05-03 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
CN114206340A (zh) 2019-05-14 2022-03-18 豪夫迈·罗氏有限公司 使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
MX2021015212A (es) 2019-06-11 2022-04-06 Alector Llc Anticuerpos antisortilina para uso en terapia.
PE20220487A1 (es) 2019-07-31 2022-04-04 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos
KR102509648B1 (ko) 2019-08-06 2023-03-15 아프리노이아 테라퓨틱스 리미티드 병리학적 타우 종에 결합하는 항체 및 이의 용도
US20210047425A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
CN114340675A (zh) 2019-09-12 2022-04-12 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
JP2022549218A (ja) 2019-09-20 2022-11-24 ジェネンテック， インコーポレイテッド 抗トリプターゼ抗体の投薬
MX2022003610A (es) 2019-09-27 2022-04-20 Genentech Inc Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
CN114829401A (zh) 2019-09-27 2022-07-29 南京金斯瑞生物科技有限公司 抗vhh域抗体及其用途
WO2021059075A1 (en) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
CN114945386A (zh) 2019-10-18 2022-08-26 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
KR20220092580A (ko) 2019-11-06 2022-07-01 제넨테크, 인크. 혈액암의 치료를 위한 진단과 치료 방법
CN115151307A (zh) 2019-12-13 2022-10-04 艾莱克特有限责任公司 抗mertk抗体和其使用方法
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
PE20221585A1 (es) 2019-12-27 2022-10-06 Chugai Pharmaceutical Co Ltd Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20230312704A1 (en) 2020-02-10 2023-10-05 Shanghai Escugen Biotechnology Co., Ltd. Cldn18.2 antibody and use thereof
KR20220140786A (ko) 2020-02-10 2022-10-18 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 클라우딘18.2 항체 및 그것의 사용
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
IL295023A (en) 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and their uses
AU2021225920A1 (en) 2020-02-28 2022-09-15 Shanghai Henlius Biotech, Inc. Anti-CD137 construct and use thereof
CA3169910A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
CN115605507A (zh) 2020-03-13 2023-01-13 基因泰克公司（Us） 抗白介素-33抗体及其用途
CN117510630A (zh) 2020-03-19 2024-02-06 基因泰克公司 同种型选择性抗TGF-β抗体及使用方法
CR20220489A (es) 2020-03-24 2022-10-31 Genentech Inc Agentes de fijación a tie2 y métodos de uso.
EP4126937A1 (en) 2020-03-31 2023-02-08 Alector LLC Anti-mertk antibodies and methods of use thereof
CA3170570A1 (en) 2020-04-01 2021-10-07 James J. KOBIE Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
IL297541A (en) 2020-04-24 2022-12-01 Genentech Inc Methods for using anti-cd79b immunoconjugates
WO2021222935A2 (en) 2020-04-28 2021-11-04 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
EP4146283A1 (en) 2020-05-03 2023-03-15 Levena (Suzhou) Biopharma Co., Ltd. Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
US20230220057A1 (en) 2020-05-27 2023-07-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
AU2021283345A1 (en) 2020-06-02 2023-02-02 Dynamicure Biotechnology Llc Anti-CD93 constructs and uses thereof
WO2021252977A1 (en) 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
MX2022015881A (es) 2020-06-18 2023-01-24 Genentech Inc Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
KR20230042032A (ko) 2020-07-21 2023-03-27 제넨테크, 인크. Brm 분해의 항체 접합 화학 유도제 및 이의 방법
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
KR20230133832A (ko) 2020-07-29 2023-09-19 다이내믹큐어 바이오테크놀로지 엘엘씨 항-cd93 구축물 및 그의 용도
CN114360436B (zh) 2020-09-28 2023-03-10 京东方科技集团股份有限公司 补偿显示画面的方法、装置、设备及显示屏驱动板
KR20230091871A (ko) 2020-10-20 2023-06-23 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항제 및 lrrk2 억제제의 병용 요법
AR124562A1 (es) 2020-10-28 2023-04-12 Hoffmann La Roche Receptores de unión al antígeno mejorada
IL302400A (en) 2020-11-04 2023-06-01 Genentech Inc Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP4240493A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
EP4240758A1 (en) 2020-11-04 2023-09-13 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
KR20230117169A (ko) 2020-12-02 2023-08-07 알렉터 엘엘씨 항-소르틸린 항체의 사용 방법
CN116670166A (zh) 2020-12-07 2023-08-29 Ucb生物制药有限责任公司 多特异性抗体和抗体组合
AU2021398385A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Antibodies against interleukin-22
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
AU2021399841A1 (en) 2020-12-17 2023-07-06 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
WO2022155324A1 (en) 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
CN117396502A (zh) 2021-02-09 2024-01-12 佐治亚大学研究基金会有限公司 针对肺炎球菌抗原的人类单克隆抗体
IL304955A (en) 2021-02-09 2023-10-01 Us Health Antibodies targeting the spike protein of a coronavirus
JP2024509169A (ja) 2021-03-03 2024-02-29 ソレント・セラピューティクス・インコーポレイテッド 抗ｂｃｍａ抗体を含む抗体－薬物コンジュゲート
JP2024509191A (ja) 2021-03-05 2024-02-29 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａ構築物およびその使用
CA3213599A1 (en) 2021-03-15 2022-09-22 Genentech, Inc. Compositions and methods of treating lupus nephritis
JP2024512002A (ja) 2021-03-18 2024-03-18 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
EP4314063A1 (en) 2021-03-23 2024-02-07 Alector LLC Anti-tmem106b antibodies for treating and preventing coronavirus infections
TW202300648A (zh) 2021-03-25 2023-01-01 美商當康生物科技有限公司 抗-igfbp7構築體及其用途
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
IL307821A (en) 2021-04-30 2023-12-01 Hoffmann La Roche Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
CN117642428A (zh) 2021-05-03 2024-03-01 Ucb生物制药有限责任公司 抗体
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
CA3218170A1 (en) 2021-05-12 2022-11-17 Jamie Harue HIRATA Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN113278071B (zh) 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
TW202306994A (zh) 2021-06-04 2023-02-16 日商中外製藥股份有限公司 抗ddr2抗體及其用途
CA3216220A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
CN117642426A (zh) 2021-06-16 2024-03-01 艾莱克特有限责任公司 双特异性抗MerTK和抗PDL1抗体及其使用方法
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2022270611A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体
BR112023023480A2 (pt) 2021-06-25 2024-01-30 Chugai Pharmaceutical Co Ltd Uso de anticorpo anti-ctla-4
TW202317633A (zh) 2021-07-08 2023-05-01 美商舒泰神（加州）生物科技有限公司 特異性識別ｔｎｆｒ２的抗體及其用途
CN115812082A (zh) 2021-07-14 2023-03-17 舒泰神（北京）生物制药股份有限公司 特异性识别cd40的抗体及其应用
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof
WO2023019239A1 (en) 2021-08-13 2023-02-16 Genentech, Inc. Dosing for anti-tryptase antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023034750A1 (en) 2021-08-30 2023-03-09 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023058705A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体の製剤
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
TW202346365A (zh) 2022-03-23 2023-12-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療
WO2023180511A1 (en) 2022-03-25 2023-09-28 F. Hoffmann-La Roche Ag Improved chimeric receptors
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023215737A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2023250402A2 (en) 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2024020407A1 (en) 2022-07-19 2024-01-25 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024049949A1 (en) 2022-09-01 2024-03-07 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10333631A (ja) * 1997-06-02 1998-12-18 Daichiyuu Denshi:Kk 拡張型表示装置および拡張型表示装置を用いた表示システム
US6278434B1 (en) * 1998-10-07 2001-08-21 Microsoft Corporation Non-square scaling of image data to be mapped to pixel sub-components
GB0006811D0 (en) 2000-03-22 2000-05-10 Koninkl Philips Electronics Nv Controller ICs for liquid crystal matrix display devices
TW518882B (en) * 2000-03-27 2003-01-21 Hitachi Ltd Liquid crystal display device for displaying video data
JP2002323876A (ja) 2001-04-24 2002-11-08 Nec Corp 液晶表示装置における画像表示方法及び液晶表示装置
US7587671B2 (en) * 2005-05-17 2009-09-08 Palm, Inc. Image repositioning, storage and retrieval
CN100380189C (zh) 2006-03-10 2008-04-09 友达光电股份有限公司 液晶显示面板动态影像的显示方法

Also Published As

Publication number Publication date
US20090002360A1 (en) 2009-01-01
US8054268B2 (en) 2011-11-08
CN101312015A (zh) 2008-11-26

Similar Documents

Publication Publication Date Title
CN100592373C (zh) 液晶显示面板驱动装置及其驱动方法
US9530380B2 (en) Display device and driving method thereof
CN102148012B (zh) 图像显示控制装置、图像显示装置及其控制方法
CN100449603C (zh) 液晶显示器件的驱动装置和方法
CN102903347B (zh) 一种有效解决液晶显示屏阳光下显示不清晰的方法及***
CN100573634C (zh) 显示器件及其驱动方法
US8416269B2 (en) Liquid crystal display device and driving method thereof
KR101337042B1 (ko) 터치패널 표시장치 및 그의 구동방법
CN109616067B (zh) 一种电压补偿电路及其方法、显示驱动电路、显示装置
CN102750927A (zh) 依据环境光的亮度调整画面灰阶度的显示装置及方法
CN101097319B (zh) 液晶显示装置及其驱动方法
CN111312143A (zh) 显示装置及其驱动方法和驱动装置、计算机可读存储介质
CN101110198A (zh) 等离子显示面板的驱动装置及其驱动方法
CN106128371A (zh) 一种画面亮度增强的装置、显示设备及方法
CN102214450B (zh) 液晶显示器及其驱动方法
CN101930715B (zh) 插灰驱动电路及其方法
CN101320544B (zh) 数据处理电路、液晶显示装置及其驱动方法
US10565940B2 (en) Display device having optical sensor
KR101348700B1 (ko) 액정표시장치 및 그 구동방법
US11335276B2 (en) Display driving device and driving method of adjusting brightness of image based on ambient illumination
CN114495791A (zh) 显示面板的显示控制方法、装置及显示装置
CN114530129A (zh) 显示面板的驱动方法、显示面板的驱动装置及显示设备
CN101266760B (zh) 在液晶显示器中整合反交错及过驱动以处理影像数据的方法及***
CN113870808B (zh) 一种时序控制方法、时序控制器、存储介质和计算机设备
CN101593494A (zh) 液晶显示器及其驱动方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100224

Termination date: 20200525